Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 13:15:374-378.
doi: 10.18632/oncotarget.28591.

When does a melanoma metastasize? Implications for management

Affiliations
Review

When does a melanoma metastasize? Implications for management

John F Thompson et al. Oncotarget. .

Abstract

Selecting which patients with clinically-localized melanoma require treatment other than wide excision of the primary tumor is based on the risk or presence of metastatic disease. This in turn is linked to survival. Knowing if and when a melanoma is likely to metastasize is therefore of great importance. Several studies employing a range of different methodologies have suggested that many melanomas metastasize long before the primary lesion is diagnosed. Therefore, waiting for dissemination of metastatic disease to become evident before making systemic therapy available to these patients may be less effective than giving them post-operative adjuvant therapy initially if the metastatic risk is high. The identification of these high-risk patients will assist in selecting those to whom adjuvant systemic therapy can most appropriately be offered. Further studies are required to better identify high-risk patients whose primary melanoma is likely to have already metastasized.

Keywords: adjuvant systemic therapy; melanoma; metastasis; time; tumor doubling time.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

JFT has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Biopharmaceuticals, and travel and conference support from GSK, Provectus Biopharmaceuticals and Novartis. GJW has no conflicts of interest to declare.

Figures

Figure 1
Figure 1. Backwards extrapolation of median sentinel node tumor diameter prior to the time of primary melanoma diagnosis in a population-based cohort of 1027 Dutch melanoma patients (reproduced with permission from European Journal of Cancer 167: 133–141, 2022 [25]).

References

    1. Xiong DD, Barriera-Silvestrini P, Knackstedt TJ. Delays in the surgical treatment of melanoma are associated with worsened overall and melanoma-specific mortality: A population-based analysis. J Am Acad Dermatol. 2022; 87:807–14. 10.1016/j.jaad.2022.06.1190. - DOI - PubMed
    1. Conic RZ, Cabrera CI, Khorana AA, Gastman BR. Determination of the impact of melanoma surgical timing on survival using the National Cancer Database. J Am Acad Dermatol. 2018; 78:40–46.e7. 10.1016/j.jaad.2017.08.039. - DOI - PMC - PubMed
    1. Hewitt DB, Beane JD, Grignol VP, Contreras CM. Association between surgical delay and outcomes among patients with invasive cutaneous melanoma. Am J Surg. 2023; 226:631–39. 10.1016/j.amjsurg.2023.04.019. - DOI - PubMed
    1. Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, et al., and KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022; 399:1718–29. 10.1016/S0140-6736(22)00562-1. - DOI - PubMed
    1. Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, et al.. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023; 29:2835–43. 10.1038/s41591-023-02583-2. - DOI - PMC - PubMed